Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial

David Cunningham*, Sally P. Stenning, Elizabeth C. Smyth, Alicia F. Okines, William H. Allum, Sam Rowley, Laura Stevenson, Heike I. Grabsch, Derek Alderson, Thomas Crosby, S. Michael Griffin, Wasat Mansoor, Fareeda Y. Coxon, Stephen J. Falk, Suzanne Darby, Kate A. Sumpter, Jane M. Blazeby, Ruth E. Langley

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)357-370
Number of pages14
JournalLancet oncology
Volume18
Issue number3
DOIs
Publication statusPublished - Mar 2017

Keywords

  • PATHOLOGICAL COMPLETE RESPONSE
  • ADVANCED GASTRIC-CANCER
  • BREAST-CANCER
  • GASTROESOPHAGEAL ADENOCARCINOMA
  • RECTAL-CANCER
  • DOUBLE-BLIND
  • NEOADJUVANT BEVACIZUMAB
  • PLUS BEVACIZUMAB
  • III TRIAL
  • SURGERY

Cite this

Cunningham, D., Stenning, S. P., Smyth, E. C., Okines, A. F., Allum, W. H., Rowley, S., Stevenson, L., Grabsch, H. I., Alderson, D., Crosby, T., Griffin, S. M., Mansoor, W., Coxon, F. Y., Falk, S. J., Darby, S., Sumpter, K. A., Blazeby, J. M., & Langley, R. E. (2017). Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet oncology, 18(3), 357-370. https://doi.org/10.1016/S1470-2045(17)30043-8